Skip to main content
SpringerLink
Log in
Book cover

Male Sexual Function pp 271–286Cite as

Oral Therapy for Erectile Dysfunction

  • Chapter

  • 960 Accesses

Part of the book series: Current Clinical Urology ((CCU))

Abstract

Oral medications are first-line treatment for erectile dysfunction (ED). They are attractive to patients and physicians because of the ease of use and discrete nature of delivery compared with other treatment options. Among all the treatments for ED, the oral agents have been the most rigorously studied. Effective oral therapy for ED was first introduced in 1998 with the approval of the first phosphodiesterase type 5 inhibitor, Viagra®, and was soon followed by vardenafil (Levitra®) and tadalafil (Cialis®) in 2003. Oral pharmacotherapy has important considerations, including time to onset, food interactions, duration of action, drug-drug interactions, systemic side effects, and clinical efficacy. This chapter focuses on the efficacy of oral pharmacotherapy for the treatment of ED and includes discussions on historical treatments, homeopathic remedies, drug discovery, pharmacology of phosphodiesterase type 5 inhibitors, pharmacokinetics and dynamics, clinical trials experience, and future directions.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Reid K, Surridge DH, Morals A, et al. Double-blind trial of yohimbine in treatment of psychogenic impotence. Lancet 1987; 2: 421–423.

    Article  PubMed  CAS  Google Scholar 

  2. Rytter M. Z Haut Geschlechtskr 1973; 48: 481–486.

    PubMed  CAS  Google Scholar 

  3. Broderick GA, Lue TF. Evaluation and nonsurgical management of erectile dysfunction and priapism. In: Walsh P, Retik A, Vaughan D, Wein A, eds. Campbell’s Urology, 8th ed. Saunders, Philadelphia, 2002, 1619–1671.

    Google Scholar 

  4. Rajfer J, Aaronson WS, Bush PA, Dorey FJ, Ignarro LJ. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992; 326: 90–94.

    Article  PubMed  CAS  Google Scholar 

  5. Bischoff E. Pharmacology of phosphodiesterase inhibitors. In: Broderick GA, ed. Oral Pharmacotherapy for Male Sexual Dysfunction: A Guide to Clinical Management, 1st ed. Totowa, Humana Press, 2005, 43–64.

    Google Scholar 

  6. Haning H, Niewohner U, Bischoff E. PDE type 5 (PDE5) inhibitors. Prog Med Chem 2003; 41: 249–310.

    Article  PubMed  CAS  Google Scholar 

  7. Padma-Nathan H. Sildenafil citrate, the classical PDE5 inhibitor. In: Broderick GA, ed. Oral Pharmacotherapy for Male Sexual Dysfunction: A Guide to Clinical Management, 1st ed. Totowa, Humana Press, 2005, 65–83.

    Google Scholar 

  8. Turko IV, Ballard SA, et al. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (type 5) by sildenafil and related compounds. Mol Pharmacol 1999; 56: 124–130.

    PubMed  CAS  Google Scholar 

  9. Saenz de Tajeda I, Angulo J, et al. The phosphodiesterase inhibitory selectivity and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 2001; 13: 282–290.

    Article  Google Scholar 

  10. Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitor. Int J Clin Pract 2002; 56: 453–459.

    PubMed  CAS  Google Scholar 

  11. Gbekor E, Bethell S, et al. Selectivity and other phosphodiesterase type 5 (PDE5) inhibitors against all human phosphodiesterase families. Eur Urol 2002; 1(Suppl 1): 63.

    Google Scholar 

  12. Padma-Nathan H, Stecher V, Sweeney M, et al. Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebo-controlled trial. Urology 2003; 62: 400–403.

    Article  PubMed  CAS  Google Scholar 

  13. Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil citrate after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol 2002; 53(Suppl 1): S5–S12.

    Article  Google Scholar 

  14. Porst H, Padma-Nathan H, Giuliano F, et al. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology 2003; 62: 121–126.

    Article  PubMed  Google Scholar 

  15. Eid JF, Hatzichristou DG, Whitaker S, et al. Tadalafil is effective for 36 hours in men with erectile dysfunction-results from an 11-study integrated analysis.(abstract 30) Int J Impot Res 2003; 15(Suppl 5): S175.

    Google Scholar 

  16. Padma-Nathan H, Rosen RC, Shasbigh R, Saikali K. Cialis (IC351) provides prompt response and extended period of responsiveness for the treatment of men with erectile dysfunction (ED). J Urol 2001; 165(Suppl 5): 224 [abstract #923].

    Google Scholar 

  17. Sachse R, Rohde G, Stark S, et al. Safety, tolerability and Pharmacokinetics of BAY 38-9456 in patients with erectile dysfunction. J Urol 2000; 163: 204.

    Google Scholar 

  18. Porst H, Steidle C, Hollister A, et al. Vardenafil demonstrated similar efficacy and tolerability among older and younger patients with marginal differences in PK characteristics between age groups. Int J Impot Res 2001; 13: 45.

    Article  Google Scholar 

  19. Rajagopalan P, Mazzu A, Xia C, et al. Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol 2003; 43: 260–267.

    Article  PubMed  CAS  Google Scholar 

  20. Bauer RJ, Rohde G, Wensing G. Evaluation of the interactions of alcohol and PDE5 inhibitor, vardenafil. Int J Impot Res 2002; 14(Suppl 4): S22–S59.

    Google Scholar 

  21. Montrosi F, Padma-Nathan H, Buvat J, et al. Earliest time to onset of action leading to successful intercourse with vardenafil determined in an at-home setting: a randomized, double-blind, placebocontrolled trial. J Sex Med 2004; 1: 168–178.

    Article  Google Scholar 

  22. Sadovsky R, Miller T, Moskowitz M, Hackett G. Three year update of sildenafil citrate (Viagra) efficacy and safety. Int J Clin Pract 2001; 55: 115–128.

    PubMed  CAS  Google Scholar 

  23. Herrmann HC, Chang G, Klugherz BD, et al. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000; 342: 1622–1626.

    Article  PubMed  CAS  Google Scholar 

  24. Laties A, Zrenner E. Viagra (sildenafil citrate) and ophthalmology. Prog Retin Eye Res 2002; 21: 485–506.

    Article  PubMed  CAS  Google Scholar 

  25. Montrosi F, Verheyden B, Junemann KP, et al. Long-term safety experience with tadalafil. J Urol 2003; 169(Suppl 4): 245 [abstract #947].

    Google Scholar 

  26. Hayref S. Erectile dysfunction drugs and non-arteritic anterior ischemic optic neuropathy: is there a cause and effect relationship? J Neuroophthalmol 2005; 25: 295–298.

    Google Scholar 

  27. Pomeranz HD, Bhavsar AR. Nonarteritic ischemic optic neuropathy developing soon after use of sildenafil (viagra): a report of seven new cases. J of Neuro-Ophthalmol 2005; 25(1): 9–13.

    Article  Google Scholar 

  28. Shakir SAW. ESSIR Annual Meeting. Hamburg, Germany 2002.

    Google Scholar 

  29. Padma-Nathan H, Eardley I, Kloner R, et al. A four-year update on the safety of sildenafil citrate (Viagra). Urology 2002; 60(Suppl 2B): 67–90.

    Article  PubMed  Google Scholar 

  30. Kloner R, Mohan P, Norenberg C, et al. Cardiovascular safety of vardenafil, a potent, highly selective PDE-5 inhibitor in patients with erectile dysfunction: an analysis of five placebo-controlled clinical trials. Pharmacotherapy 2002; 22: 1371.

    Google Scholar 

  31. Viagra® (sildenafil) prescribing information. (2003) New York, NY: Pfizer Inc. Available at Website: http://www.fda.gov/cder/foi/label/1998/viagralabel2.pdf.

  32. Aversa A, Mazzilli F, Rossi T, et al. Effects of sildenafil administration on seminal parameters and post-ejaculatory refractory time in normal males. Human Reproduction 2000; 15(1): 131–134.

    Article  PubMed  CAS  Google Scholar 

  33. Mondaini N, Ponchietti R, Muir GH, et al. Sildenafil does not improve sexual function in men without erectile dysfunction but does reduce the postorgasmic refractory time. Int J Impot Res 2003; 15: 225–228.

    Article  PubMed  CAS  Google Scholar 

  34. Abdel-Hamid IA. Phosphodiesterase 5 inhibitors in rapid ejaculation: potential use and possible mechanisms of action. Drugs 2004; 64(1): 13–26.

    Article  PubMed  CAS  Google Scholar 

  35. Chen J, Mabjeesh NJ, Matzkin H, Greenstein H. Efficacy of sildenafil as adjuvant therapy to selective serotonin reuptake inhibitor in alleviating premature ejaculation. Urology 2003; 61(1): 197–200.

    Article  PubMed  Google Scholar 

  36. Salonia A, Maga T, Colombo R, et al. A prospective study comparing paroextine alone versus paroxetine plus sildenafil in patients with premature ejaculation. J Urol 2002; 168(6): 2486–2489.

    Article  PubMed  CAS  Google Scholar 

  37. Purvis K, Muirhead GJ, Harness JA. The effects of sildenafil on human sperm function in healthy volunteers. Br J Clin Pharmacol 2002; 53(Suppl 1): S53–S60.

    Article  Google Scholar 

  38. Hellstrom WJG, Overstreet JW, Yu A, et al. Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. J Urol 2003; 170: 887–891.

    Article  PubMed  CAS  Google Scholar 

  39. Nehra A. Vardenafil: clinical trials experience. In: Broderick GA, ed. Oral Pharmacotherapy for Male Sexual Dysfunction: A Guide to Clinical Management, 1st ed. Totowa, Humana Press, 2005, 109–148.

    Google Scholar 

  40. Carson CC, Burnett AL, Levine LA, et al. The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology 2002; 60(Suppl 2B): 12–27.

    Article  PubMed  Google Scholar 

  41. Goldfischer E, Eardley I, Segerson T, et al. Vardenafil improves erectile function in men with significant comorbidities associated with erectile dysfunction. J Urol 2002; 167(Suppl): 178.

    Google Scholar 

  42. Hellstrom WJ, Gittelman M, Karlin G, et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002; 23: 763–771.

    PubMed  CAS  Google Scholar 

  43. Brock GB, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of an integrated analysis. J Urol 2002; 168: 1332–1336.

    Article  PubMed  CAS  Google Scholar 

  44. Carson C, Porst H, Kaufman JM, et al. Tadalafil is effective in treating mild to severe erectile dysfunction. Int J Impot Res 2003; 15(Suppl 5): S174 [abstract 28].

    Google Scholar 

  45. Lewis RG, Sadovsky R, Eardley I, et al. The efficacy of tadlafil in clinical populations. J Sex Med 2005; 2: 517–531.

    Article  PubMed  CAS  Google Scholar 

  46. Hong EK, Lepor H, McCullough AR. Time dependent patient satisfaction with sildenafil for erectile dysfunction after nerve-sparing radical retropubic prostatectomy. Int J Impot Res 1999; 11(Suppl I): S15–S22.

    Article  PubMed  Google Scholar 

  47. McCullough AR. Prevention and management of erectile dysfunction following radical prostatectomy. Urol Clin N Am 2001; 28: 613–627.

    Article  CAS  Google Scholar 

  48. Brock G, Lipshultz L, Karlin G, et al. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction subsequent to radical retropubic prostatectomy. J Urol 2003; 170: 1278–1283.

    Article  PubMed  CAS  Google Scholar 

  49. Brock G, Vezina JG, Nehra A, et al. Vardenafil improved patient satisfaction with erection hardness, orgasmic function, and sexual experience in men with erectile dysfunction following nerve-sparing radical prostatectomy. Prog Urol 2003; 13(Suppl 2): 32 [abstract 104].

    Google Scholar 

  50. Padma-Nathan H, McCullough A, Giuliano F, et al. Postoperative nightly administration of sildenafil citrate significantly improves the return of normal spontaneous erectile function after bilateral nerve-sparing radical prostatectomy. (abstract) Presented at the AUA Annual Meeting, Chicago, IL, April 27, 2004.

    Google Scholar 

  51. Hisasue S, Kato R, Takahashi A, et al. Erectile function following external beam radiotherapy for clinically organ-confined or locally advanced prostate cancer. Jap J Clin Oncol 2004; 34(5): 269–273.

    Article  Google Scholar 

  52. Little DJ, Kuban DA, Levy LB, et al. Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology 2003; 62(4): 707–713.

    Article  PubMed  Google Scholar 

  53. Shemtov OM, Radomski SB, Crook J. Success of sildenafil for erectile dysfunction in men treated with brachytherapy or external beam radiation for prostate cancer. Can J Urol 2004; 11(6): 2450–2455.

    PubMed  Google Scholar 

  54. Raina R, Agarwal A, Goyal KK, et al. Long-term potency after iodine-125 radiotherapy for prostate cancer and role of sildenafil citrate. Urology 2003; 62(6): 1103–1108.

    Article  PubMed  Google Scholar 

  55. McCullough AR, Barada JH, Fawzy A, et al. Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology 2002; 60(sUPPL 2b): 28–38.

    Article  PubMed  Google Scholar 

  56. Carson C, Hatzichristou D, Carrier S, et al. Vardenafil exhibits efficacy in men with erectile dysfunction unresponsive to prior sildenafil therapy: results of a phase III clinical trial-Patient Response with Vardenafil in Sildenafil nonresponders (PROVEN). Int J Impot Res 2003; 15(Suppl 5): S175.

    Google Scholar 

  57. Brisson T, Broderick GA, Pinkstaff D. Can patients failing a PDE-5 inhibitor be rescued by another tablet? An objective assessment of 331 patients with erectile dysfunction. J Urol 2005; 173: 236.

    Google Scholar 

  58. Klotz T, Mathers M, Klotz R, Sommer F. Why do patients with erectile dysfunction abandon effective therapy with sildenafil (Viagra)? Int J Impot Res 2005; 17: 2–4.

    Article  PubMed  CAS  Google Scholar 

  59. Mulhall JP. Understanding erectile dysfunction medication preference studies. Curr Opin Urol 2004; 14: 367–373.

    Article  PubMed  Google Scholar 

  60. McMahon CM, Kozlowski RK, Kaufman AK, et al. Potential predictors for treatment preference in men with erectile dysfunction taking sildenafil and tadalafil in an open-label switch trial. J Sex Med 2004; 1: 40 [abstract O37].

    Article  Google Scholar 

  61. Rubio-Aurioles E, Chen KK, Adbo CH, et al. Psychological and interpersonal relationship scales for tadalafil (Cialis) and sildenafil citrate (Viagra) in men with erectile dysfunction. J Sex Med 2004; 1: 40 [abstract O38].

    Article  Google Scholar 

  62. Glina S, Sotomayor M, Gatchalian ER, et al. Timing of dose relative to sexual intercourse attempts in men with erectile dysfunction treated with tadalafil (Cialis) and sildenafil citrate (Viagra): relationship to treatment preference. J Sex Med 2004; 1: 56 [abstract O88].

    Google Scholar 

  63. Stroberg P, Ljunggren CR, Hedelin H. Patient preference in clinical practice in treatment of erectile dysfunction with PDE-5 inhibitors. J Sex Med 2004; 1: 41 [abstract O40].

    Google Scholar 

  64. Claes HIM, Van Poppel H. The use of sildenafil, tadalfil and vardenafil in clinical practice. J Sex Med 2004; 1: 42 [abstract O43].

    Google Scholar 

  65. Park NC, Park HJ, Nam JK, Kim JM. Efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalfil: results of open label study of patient preference in Korea. J Sex Med 2004; 1: 55 [abstract O84].

    Google Scholar 

  66. Zermann DH, Cdreihaupt M, Scubert J. Patient preference and satisfaction with different phosphodiesterase-5 inhibitors-a comparison of sildeanfil, tadalafil and vardenafil. J Sex Med 2004; 1: 55 [abstract O85].

    Google Scholar 

  67. Govier F, Potempa AJ, et al. A multicente, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction. Clin Ther 2003; 25(11): 2709–2723.

    Article  PubMed  CAS  Google Scholar 

  68. Von Keitz A, Rajfer J, Segal S, et al. A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. Eur Urol 2004; 45: 499–509.

    Article  CAS  Google Scholar 

  69. Broderick GA. Comparative Efficacy and Patient Preferences for PDE-5 Inhibitors. (2004) Available at Website: http://www.medscape.com/viewprogram/3644pnt. Accessed August 2005.

  70. Moyad MA, Barada JA, et al. Prevention and treatment of erectile dysfunction using lifestyle changes and dietary supplements: what works and what is worthless, part II. Urol Clin N Am 2004; 31: 259–273.

    Article  Google Scholar 

  71. Stanislavov R, Nikolova V. Treatment of erectile dysfunction with pycnogenol and L-arginine. J Sex Mar Ther 2003; 29(3): 207–213.

    Article  CAS  Google Scholar 

  72. Wheatley D. Triple-blind, placebo-controlled trial of Ginko biloba in sexual dysfunction due to antidepressant drugs. Human Psychopharmacol 2004; 19(8): 545–548.

    Article  Google Scholar 

  73. Hopps CV, Mulhall JP. Novel agents for sexual dysfunction. BJU Int 2003; 92: 534–538.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Raymond W. Pak MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gregory A. Broderick MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Pak, R.W., Broderick, G.A. (2006). Oral Therapy for Erectile Dysfunction. In: Male Sexual Function. Current Clinical Urology. Humana Press. https://doi.org/10.1007/978-1-59745-155-0_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-155-0_12

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-747-1

  • Online ISBN: 978-1-59745-155-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation